Review



non targeting control shrna sequences  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology non targeting control shrna sequences
    Non Targeting Control Shrna Sequences, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/CtBP2+shRNA+(h)+Lentiviral+Particles/pm40038783-68-14-21
    Average 94 stars, based on 1 article reviews
    non targeting control shrna sequences - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Plasmid Preparation:

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment.
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Nontransduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: CtBP2 triggers CCN1-induced metastatic dissemination of osteosarcoma cells in a non-hypoxic microenvironment
    Article Snippet: Culture media were changed three times a week, and regularly tested for mycoplasma contamination (PCR-based assay from Minerva-Biolabs, Berlin, Germany). .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    shRNA:

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment.
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Nontransduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
    Article Snippet: .. The next day, cells were transduced with lentiviral particles encoding human sh-MT2A, murine sh-MT2 or non-targeting (control) shRNA sequences purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), according to the manufacturer’s instructions. ..

    Article Title: CtBP2 triggers CCN1-induced metastatic dissemination of osteosarcoma cells in a non-hypoxic microenvironment
    Article Snippet: Culture media were changed three times a week, and regularly tested for mycoplasma contamination (PCR-based assay from Minerva-Biolabs, Berlin, Germany). .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Control:

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment.
    Article Snippet: .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Nontransduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Article Title: MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
    Article Snippet: .. The next day, cells were transduced with lentiviral particles encoding human sh-MT2A, murine sh-MT2 or non-targeting (control) shRNA sequences purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), according to the manufacturer’s instructions. ..

    Article Title: CtBP2 triggers CCN1-induced metastatic dissemination of osteosarcoma cells in a non-hypoxic microenvironment
    Article Snippet: Culture media were changed three times a week, and regularly tested for mycoplasma contamination (PCR-based assay from Minerva-Biolabs, Berlin, Germany). .. Ready-to-use lentiviral particles containing a vector encoding human or murine CtBP2 shRNA sequences or non-targeting (control) shRNA sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). .. Briefly, sub-confluent target cells were incubated with particles and 4 μg/mL polybrene (Hexadimethrine bromide; Sigma-Aldrich, Lyon, France) for 18 h, washed once with medium, and cultured for 48 h. Non-transduced cells were eliminated by puromycin dihydrochloride selection (10 μg/mL; Sigma-Aldrich) for 3 days.

    Transduction:

    Article Title: MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
    Article Snippet: .. The next day, cells were transduced with lentiviral particles encoding human sh-MT2A, murine sh-MT2 or non-targeting (control) shRNA sequences purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), according to the manufacturer’s instructions. ..



    Similar Products

    shrna sequences targeting mettl16 and pparγ, and non-targeting negative control (sh-nc)  (Shanghai GenePharma)
    90
    Shanghai GenePharma shrna sequences targeting mettl16 and pparγ, and non-targeting negative control (sh-nc)
    Shrna Sequences Targeting Mettl16 And Pparγ, And Non Targeting Negative Control (Sh Nc), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/shrna+sequences+targeting+mettl16+and+ppar%CE%B3++and+non+targeting+negative+control++sh+nc+/pm40210616-115-5-16
    Average 90 stars, based on 1 article reviews
    shrna sequences targeting mettl16 and pparγ, and non-targeting negative control (sh-nc) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non targeting control shrna sequences  (Santa Cruz Biotechnology)
    94
    Santa Cruz Biotechnology non targeting control shrna sequences
    Non Targeting Control Shrna Sequences, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/CtBP2+shRNA+(h)+Lentiviral+Particles/pm40038783-68-14-21
    Average 94 stars, based on 1 article reviews
    non targeting control shrna sequences - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    non targeting control sequence si nc  (OriGene)
    92
    OriGene non targeting control sequence si nc
    Non Targeting Control Sequence Si Nc, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/MGC35030+Human+shRNA+Lentiviral+Particle/pm39152325-54-11-18
    Average 92 stars, based on 1 article reviews
    non targeting control sequence si nc - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    non targeting randomized shrna sequence  (Addgene inc)
    93
    Addgene inc non targeting randomized shrna sequence
    Fig. 2 USP9x regulates tumor growth and is elevated in human lung cancer. A Knockdown efficiency of stable inducible <t>shRNA-expressing</t> NCI-H1975 cells following induction for 48 h with 20 ng/mL doxycycline. B Clonogenicity with quantification (n = 3). C Cell growth over 4 days upon USP9x knockdown in NCI-H1975 normalized to the non-targeting shRNA control (n = 3). D Cell growth as in (C) in A549 and NCI-H2087 cancer cells upon USP9x knockdown for 48 h (n = 3). E Measurement of cell toxicity upon USP9x knockdown in the cell line panel (n = 3). F Knockdown efficiency in xenograft tumors from shRNA-mediated USP9x knockdown cells in mice, (n = 6 per condition). G Individual tumor growth of USP9x knockdown tumors measured over 14 days. Statistical significance calculated with t-tests from the average of each group on day 14. H Tumor weight of USP9x knockdown tumors from (F). I RNA expression of USP9x in lung adenocarcinoma patient samples (n = 535) vs. normal lung samples (n = 59) obtained from the TCGA database. J Representative immunohistochemistry staining for USP9x in lung adenocarcinoma samples (n = 142) and normal lung tissue (n = 92), the scale bar (in black) measures 10 µm. Error bars ± SD. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.
    Non Targeting Randomized Shrna Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/pLKO-Tet-On-shRNA-Control+(Plasmid+%2398398)/pm39075050-196-4-16
    Average 93 stars, based on 1 article reviews
    non targeting randomized shrna sequence - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    negative control (nc) vector (sh-nc) containing non-targeting shrna sequence  (Shanghai Genechem Ltd)
    90
    Shanghai Genechem Ltd negative control (nc) vector (sh-nc) containing non-targeting shrna sequence
    List of primers and <t> shRNA </t> sequences used.
    Negative Control (Nc) Vector (Sh Nc) Containing Non Targeting Shrna Sequence, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/shrna+sequences/pmc11015917-114-22-28
    Average 90 stars, based on 1 article reviews
    negative control (nc) vector (sh-nc) containing non-targeting shrna sequence - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non-targeting control shrna sequence  (Ribobio co)
    90
    Ribobio co non-targeting control shrna sequence
    Validation of characteristic genes in vivo (A) Relative expression levels of DDR-related genes in control and sepsis groups (n=4 in each group). (B) Relative expression levels of ARL4C in control, sepsis, <t>sepsis+Ad-shNC,</t> and sepsis+Ad-shARL4C group (n=8 in each group). (C) Expression levels of inflammatory factors (IL-1β, TNF-α, IL-10, and IL-18) in the peripheral blood of rat with sepsis+Ad-shNC and sepsis+Ad-shARL4C (n=8 in each group). (D) Survival status of rats in each group (n=10 in each group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS, no significant difference.
    Non Targeting Control Shrna Sequence, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/shrna+sequence+with+a+specific+interference+effect++sh+clasrp+/pmc10884272-118-17-25
    Average 90 stars, based on 1 article reviews
    non-targeting control shrna sequence - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    shrna/sh against pdcd4 or a non-targeting control sequence  (Shanghai GenePharma)
    90
    Shanghai GenePharma shrna/sh against pdcd4 or a non-targeting control sequence
    Validation of characteristic genes in vivo (A) Relative expression levels of DDR-related genes in control and sepsis groups (n=4 in each group). (B) Relative expression levels of ARL4C in control, sepsis, <t>sepsis+Ad-shNC,</t> and sepsis+Ad-shARL4C group (n=8 in each group). (C) Expression levels of inflammatory factors (IL-1β, TNF-α, IL-10, and IL-18) in the peripheral blood of rat with sepsis+Ad-shNC and sepsis+Ad-shARL4C (n=8 in each group). (D) Survival status of rats in each group (n=10 in each group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS, no significant difference.
    Shrna/Sh Against Pdcd4 Or A Non Targeting Control Sequence, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+targeting+control+shrna+sequences/si+pdcd4/pm38234627-40-0-35
    Average 90 stars, based on 1 article reviews
    shrna/sh against pdcd4 or a non-targeting control sequence - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 2 USP9x regulates tumor growth and is elevated in human lung cancer. A Knockdown efficiency of stable inducible shRNA-expressing NCI-H1975 cells following induction for 48 h with 20 ng/mL doxycycline. B Clonogenicity with quantification (n = 3). C Cell growth over 4 days upon USP9x knockdown in NCI-H1975 normalized to the non-targeting shRNA control (n = 3). D Cell growth as in (C) in A549 and NCI-H2087 cancer cells upon USP9x knockdown for 48 h (n = 3). E Measurement of cell toxicity upon USP9x knockdown in the cell line panel (n = 3). F Knockdown efficiency in xenograft tumors from shRNA-mediated USP9x knockdown cells in mice, (n = 6 per condition). G Individual tumor growth of USP9x knockdown tumors measured over 14 days. Statistical significance calculated with t-tests from the average of each group on day 14. H Tumor weight of USP9x knockdown tumors from (F). I RNA expression of USP9x in lung adenocarcinoma patient samples (n = 535) vs. normal lung samples (n = 59) obtained from the TCGA database. J Representative immunohistochemistry staining for USP9x in lung adenocarcinoma samples (n = 142) and normal lung tissue (n = 92), the scale bar (in black) measures 10 µm. Error bars ± SD. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

    Journal: Cell death discovery

    Article Title: Deubiquitinase USP9x regulates the proline biosynthesis pathway in non-small cell lung cancer.

    doi: 10.1038/s41420-024-02111-2

    Figure Lengend Snippet: Fig. 2 USP9x regulates tumor growth and is elevated in human lung cancer. A Knockdown efficiency of stable inducible shRNA-expressing NCI-H1975 cells following induction for 48 h with 20 ng/mL doxycycline. B Clonogenicity with quantification (n = 3). C Cell growth over 4 days upon USP9x knockdown in NCI-H1975 normalized to the non-targeting shRNA control (n = 3). D Cell growth as in (C) in A549 and NCI-H2087 cancer cells upon USP9x knockdown for 48 h (n = 3). E Measurement of cell toxicity upon USP9x knockdown in the cell line panel (n = 3). F Knockdown efficiency in xenograft tumors from shRNA-mediated USP9x knockdown cells in mice, (n = 6 per condition). G Individual tumor growth of USP9x knockdown tumors measured over 14 days. Statistical significance calculated with t-tests from the average of each group on day 14. H Tumor weight of USP9x knockdown tumors from (F). I RNA expression of USP9x in lung adenocarcinoma patient samples (n = 535) vs. normal lung samples (n = 59) obtained from the TCGA database. J Representative immunohistochemistry staining for USP9x in lung adenocarcinoma samples (n = 142) and normal lung tissue (n = 92), the scale bar (in black) measures 10 µm. Error bars ± SD. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

    Article Snippet: A plasmid with a non-targeting randomized shRNA sequence was used for control (gift from Roland Friedel (Addgene plasmid #98398; http://n2t.net/ addgene:98398; RRID:Addgene_98398), [47]).

    Techniques: Knockdown, shRNA, Expressing, Control, RNA Expression, Immunohistochemistry, Staining

    Fig. 3 USP9x controls the stability of PYCR3. A Number of unique peptides and their coverage obtained in USP9x and PYCR3 from LC-MS/ MS analysis on co-immunoprecipitation assay. B Co-immunoprecipitates from (A) resolved on western blot, normal rabbit IgG was used as control. C Ubiquitination assay showing the levels of ubiquitinated PYCR3 in USP9x overexpression vs. control upon treatment with MG132 for 4 h. Bar graph shows quantification of ubiquitinated PYCR3 normalized to total PYCR3 levels and the control. D siRNA-mediated knockdown of USP9x, as well as (E) USP9x inhibition with the specific inhibitor FT709 for 48 h reduced PYCR3 protein levels. F USP9x overexpression elevated PYCR3 protein level. G PYCR3 transcription upon USP9x siRNA-mediated knockdown remained unchanged. All quantifications pooled from 3 independent biological replicates. Error bars, ± SD. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

    Journal: Cell death discovery

    Article Title: Deubiquitinase USP9x regulates the proline biosynthesis pathway in non-small cell lung cancer.

    doi: 10.1038/s41420-024-02111-2

    Figure Lengend Snippet: Fig. 3 USP9x controls the stability of PYCR3. A Number of unique peptides and their coverage obtained in USP9x and PYCR3 from LC-MS/ MS analysis on co-immunoprecipitation assay. B Co-immunoprecipitates from (A) resolved on western blot, normal rabbit IgG was used as control. C Ubiquitination assay showing the levels of ubiquitinated PYCR3 in USP9x overexpression vs. control upon treatment with MG132 for 4 h. Bar graph shows quantification of ubiquitinated PYCR3 normalized to total PYCR3 levels and the control. D siRNA-mediated knockdown of USP9x, as well as (E) USP9x inhibition with the specific inhibitor FT709 for 48 h reduced PYCR3 protein levels. F USP9x overexpression elevated PYCR3 protein level. G PYCR3 transcription upon USP9x siRNA-mediated knockdown remained unchanged. All quantifications pooled from 3 independent biological replicates. Error bars, ± SD. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

    Article Snippet: A plasmid with a non-targeting randomized shRNA sequence was used for control (gift from Roland Friedel (Addgene plasmid #98398; http://n2t.net/ addgene:98398; RRID:Addgene_98398), [47]).

    Techniques: Liquid Chromatography with Mass Spectroscopy, Co-Immunoprecipitation Assay, Western Blot, Control, Ubiquitin Proteomics, Over Expression, Knockdown, Inhibition

    List of primers and shRNA sequences used.

    Journal: International Journal of Oncology

    Article Title: Knockdown of PGBD5 inhibits the malignant progression of glioma through upregulation of the PPAR pathway

    doi: 10.3892/ijo.2024.5643

    Figure Lengend Snippet: List of primers and shRNA sequences used.

    Article Snippet: The GV248 lentiviral vector containing a short hairpin RNA (shRNA) targeting PGBD5 (sh-PGBD5) and the negative control (NC) vector (sh-NC) containing a non-targeting shRNA sequence were established by Shanghai GeneChem Co., Ltd. and were ready to directly infect the cells.

    Techniques: shRNA, Sequencing

    Validation of characteristic genes in vivo (A) Relative expression levels of DDR-related genes in control and sepsis groups (n=4 in each group). (B) Relative expression levels of ARL4C in control, sepsis, sepsis+Ad-shNC, and sepsis+Ad-shARL4C group (n=8 in each group). (C) Expression levels of inflammatory factors (IL-1β, TNF-α, IL-10, and IL-18) in the peripheral blood of rat with sepsis+Ad-shNC and sepsis+Ad-shARL4C (n=8 in each group). (D) Survival status of rats in each group (n=10 in each group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS, no significant difference.

    Journal: Frontiers in Immunology

    Article Title: Prognostic stratification of sepsis through DNA damage response based RiskScore system: insights from single-cell RNA-sequencing and transcriptomic profiling

    doi: 10.3389/fimmu.2024.1345321

    Figure Lengend Snippet: Validation of characteristic genes in vivo (A) Relative expression levels of DDR-related genes in control and sepsis groups (n=4 in each group). (B) Relative expression levels of ARL4C in control, sepsis, sepsis+Ad-shNC, and sepsis+Ad-shARL4C group (n=8 in each group). (C) Expression levels of inflammatory factors (IL-1β, TNF-α, IL-10, and IL-18) in the peripheral blood of rat with sepsis+Ad-shNC and sepsis+Ad-shARL4C (n=8 in each group). (D) Survival status of rats in each group (n=10 in each group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS, no significant difference.

    Article Snippet: In summary, adenoviral vectors containing shRNA sequences specifically targeting the ARL4C gene in rats (Ad-shARL4C) alongside a non-targeting control shRNA sequence (Ad-shNC), both sourced from RiboBio in Guangzhou, China, were utilized.

    Techniques: Biomarker Discovery, In Vivo, Expressing, Control

    Validation of ARL4C in vitro . (A) Flow cytometry detected the apoptosis rate in the Control, Sepsis, Sepsis+Lv-shNC, and Sepsis+Lv-shARL4C groups. (n=4 in each group) (B) Flow cytometry detected the ROS production in the Control, Sepsis, Sepsis+Lv-shNC, and Sepsis+Lv-shARL4C groups. (n=4 in each group), *** p < 0.001, **** p < 0.001. NS, no significant difference.

    Journal: Frontiers in Immunology

    Article Title: Prognostic stratification of sepsis through DNA damage response based RiskScore system: insights from single-cell RNA-sequencing and transcriptomic profiling

    doi: 10.3389/fimmu.2024.1345321

    Figure Lengend Snippet: Validation of ARL4C in vitro . (A) Flow cytometry detected the apoptosis rate in the Control, Sepsis, Sepsis+Lv-shNC, and Sepsis+Lv-shARL4C groups. (n=4 in each group) (B) Flow cytometry detected the ROS production in the Control, Sepsis, Sepsis+Lv-shNC, and Sepsis+Lv-shARL4C groups. (n=4 in each group), *** p < 0.001, **** p < 0.001. NS, no significant difference.

    Article Snippet: In summary, adenoviral vectors containing shRNA sequences specifically targeting the ARL4C gene in rats (Ad-shARL4C) alongside a non-targeting control shRNA sequence (Ad-shNC), both sourced from RiboBio in Guangzhou, China, were utilized.

    Techniques: Biomarker Discovery, In Vitro, Flow Cytometry, Control